Common toxicities of mammalian target of rapamycin inhibitors.
about
Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinicSystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsEverolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2Nuclear DNA damage signalling to mitochondria in ageingeRapa restores a normal life span in a FAP mouse model.A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.Interventions to Slow Aging in Humans: Are We Ready?New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus.Chronological Lifespan in Yeast Is Dependent on the Accumulation of Storage Carbohydrates Mediated by Yak1, Mck1 and Rim15 Kinases.mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.Targeted agent use in cancer patients at the end of lifeOcular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE StudyManagement of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.Rapamycin increases grip strength and attenuates age-related decline in maximal running distance in old low capacity runner rats.Rapamycin, anti-aging, and avoiding the fate of TithonusRapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease.Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Autophagy in Diabetic Retinopathy.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis.Adverse events associated with mTOR inhibitors.The mTOR pathway in hepatic malignancies.Everolimus: side effect profile and management of toxicities in breast cancer.Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.Aging metabolism: intervention strategies.One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.Life-threatening dermatologic adverse events in oncologyMammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging.Does eating less make you live longer and better? An update on calorie restriction.Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.Mammalian target of rapamycin as a therapeutic target in osteoporosis.Strategies for Achieving Healthy Vascular Aging.Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study.Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer's Disease
P2860
Q26766217-75C47FA4-F324-4A40-8038-6B7E07D6602AQ26823023-763E71E9-3961-4420-AD38-9EDE6D2273D5Q28085004-744EDBAD-F57B-4696-AAD1-6F01EE9531F2Q28396642-DD6711D7-E3B9-4FEF-8159-00AD580C7CEEQ33760600-0DFE169E-81CF-44D1-921B-C99961B77A3CQ35896874-31E50B1D-34FC-4A78-AC0F-F0755F85A6C7Q35935123-53A6C9CC-7E27-4D48-8F37-63FAD87CF193Q35967285-9CB21376-8680-4C1D-821F-6D2983408B48Q36214280-683E7848-6FAE-4DEB-86B3-DF12D0B341CBQ36237523-208B74D5-EA96-44CD-BA78-64D93004513FQ36250754-04A3AC1A-D907-4908-9116-2D5833BC39DBQ36675356-BDA2E84C-ECB2-472B-B1DA-81A109AA88A4Q36722548-232B4568-D7AB-4BB7-98BF-F8481909C6EEQ36976986-AF29AA41-C1A9-4B66-AE25-3353D57118AAQ37049112-199582FB-BCE3-4ED5-803A-6FF6B1B597D8Q37052972-23F5D833-66D3-490F-B35F-81535DEBE6FEQ37514713-704A71B0-ABB5-4F70-A5F8-7D9E99B21590Q37621799-E03E8CDE-0FC1-46DA-8975-8A47B9489886Q37649641-0DAF0D36-E025-4CC3-A429-4077C37D670BQ37677015-D63B341F-00C6-4583-9160-E1C95450AE9FQ37721031-FDB2D75C-52A6-4A20-A12B-18C37C5C369AQ38028872-ADAF4B0C-D7FF-4092-91C9-E36D6B6E0A0AQ38068519-7B0ACBEA-F13C-43AF-96AD-0D43C5A5BA79Q38081396-EF3216DB-B89E-4F7A-9DB9-DBBA7EA11A12Q38125944-8DBA007F-F112-484F-AF79-D7F39231AC41Q38199328-6A4EF25E-1596-408B-924E-78643FC26FCEQ38223222-76B8A5F9-88E8-4788-A136-A4DF18307668Q38895113-516377D5-A281-4F88-ACEB-C8C659A13360Q40296763-87262BBB-4DD1-4507-A98D-50388834C34FQ41429564-BBD947E0-063A-4E28-9D04-84ABCDAEAA42Q41869634-99BF4D43-EF91-44EE-8A75-D2BD3544CC82Q44953337-707D3685-CB49-47E7-BCD2-9C6AB58749ADQ44965473-2477A187-FF73-4CD8-AF01-E8539DF7D0A3Q47119839-A0FC91F7-A3EF-4993-8925-0A388582800BQ48187280-2CC56F6F-D8A1-46EE-BFAE-F8FB0C06196CQ50133565-6BDE26BE-7DDE-4368-A23E-167F599FC778Q54858266-8064B53E-C579-4492-806C-396D3B445B72Q57174537-1D55A446-414F-4D1B-BBC7-C5537F770D79
P2860
Common toxicities of mammalian target of rapamycin inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Common toxicities of mammalian target of rapamycin inhibitors.
@en
Common toxicities of mammalian target of rapamycin inhibitors.
@nl
type
label
Common toxicities of mammalian target of rapamycin inhibitors.
@en
Common toxicities of mammalian target of rapamycin inhibitors.
@nl
prefLabel
Common toxicities of mammalian target of rapamycin inhibitors.
@en
Common toxicities of mammalian target of rapamycin inhibitors.
@nl
P2093
P2860
P1433
P1476
Common toxicities of mammalian target of rapamycin inhibitors.
@en
P2093
Anand Karnad
Andrew J Brenner
Scott A Soefje
P2860
P2888
P304
P356
10.1007/S11523-011-0174-9
P577
2011-04-16T00:00:00Z